Drugs Made In America Acquisition (DMIIR) Cash & Equivalents (2024 - 2026)
Drugs Made In America Acquisition (DMIIR) posted quarterly Cash & Equivalents of $223.0 for Q4 2025, down 98.69% year-over-year from $17035.0 in Q4 2024, and down 99.93% quarter-over-quarter from $315087.0 in Q3 2025.
Powered by 
Analysis
Drugs Made In America Acquisition (DMIIR) Cash & Equivalents (2024 - 2026) Analysis & Trends
Drugs Made In America Acquisition (DMIIR) has reported Cash & Equivalents for 2 consecutive years, with $223.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash & Equivalents fell 98.69% year-over-year to $223.0; the TTM figure through Dec 2025 stood at $223.0 (down 98.69% YoY), while the FY2025 annual figure was $223.0, down 98.69% from the prior year.
- Cash & Equivalents slipped to $223.0 in Q4 2025 per DMIIR's latest filing, from $315087.0 in the prior quarter.
- Across five years, Cash & Equivalents topped out at $315087.0 in Q3 2025 and bottomed at $223.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Cluster Group Holdings | 8.00 Bn | 8.00 Bn | - | - |
| 2 | Agriculture & Natural Solutions Acquisition | 853.42 Mn | 853.17 Mn | - | 250,000.00 |
| 3 | K&F Growth Acquisition | 836.15 Mn | 836.15 Mn | - | 92,083.00 |
| 4 | Armada Acquisition | 666.54 Mn | 666.49 Mn | - | 54,503.00 |
| 5 | Pioneer Acquisition I | 652.74 Mn | 652.27 Mn | - | 468,670.00 |
| 6 | Oxley Bridge Acquisition | 652.11 Mn | 652.11 Mn | - | 816,134.00 |
| 7 | Titan Acquisition | 651.43 Mn | 941.85 Mn | - | 247,336.00 |
| 8 | GSR IV Acquisition | 622.22 Mn | 622.22 Mn | - | 643,331.00 |
| 9 | Launch One Acquisition | 618.70 Mn | 618.70 Mn | - | 321,957.00 |
| 10 | Drugs Made In America Acquisition | 5.10 Mn | 5.10 Mn | - | 174,974.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 174,974.00 |
| Dec 31, 2025 | 223.00 |
| Sep 30, 2025 | 315,087.00 |
| Dec 31, 2024 | 17,035.00 |